Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation and Depletion (2023 - 2025)

Compass Therapeutics' Depreciation and Depletion history spans 3 years, with the latest figure at $100000.0 for Q3 2025.

  • For Q3 2025, Depreciation and Depletion fell 50.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $300000.0, down 50.0%, while the annual FY2025 figure was $300000.0, 50.0% down from the prior year.
  • Depreciation and Depletion for Q3 2025 was $100000.0 at Compass Therapeutics, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $200000.0 in Q1 2023 and bottomed at $100000.0 in Q3 2023.
  • The 3-year median for Depreciation and Depletion is $100000.0 (2023), against an average of $145454.5.
  • The largest YoY upside for Depreciation and Depletion was 100.0% in 2024 against a maximum downside of 50.0% in 2024.
  • A 3-year view of Depreciation and Depletion shows it stood at $200000.0 in 2023, then crashed by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Depreciation and Depletion are $100000.0 (Q3 2025), $100000.0 (Q2 2025), and $100000.0 (Q1 2025).